Inflammatory Bowel Diseases最新文献_第7页

Crohn's Disease Stricture Response to Treatment Assessed with Magnetic Resonance Imaging and Intestinal Ultrasound: STRIDENT Randomized Trial. 用磁共振成像和肠道超声评估克罗恩病狭窄治疗反应：STRIDENT随机试验。

IF 4.5 3区医学

Inflammatory Bowel Diseases Pub Date : 2025-05-08 DOI: 10.1093/ibd/izaf073

Grace C Lovett, Julien D Schulberg, Amy L Hamilton, Emily K Wright, Tom R Sutherland, Alyson L Ross, Michael A Kamm

{"title":"Crohn's Disease Stricture Response to Treatment Assessed with Magnetic Resonance Imaging and Intestinal Ultrasound: STRIDENT Randomized Trial.","authors":"Grace C Lovett, Julien D Schulberg, Amy L Hamilton, Emily K Wright, Tom R Sutherland, Alyson L Ross, Michael A Kamm","doi":"10.1093/ibd/izaf073","DOIUrl":"https://doi.org/10.1093/ibd/izaf073","url":null,"abstract":"Background: Transmural healing is emerging as a key treatment target in Crohn's disease. This study aimed to determine the role of magnetic resonance imaging (MRI) and intestinal ultrasound (IUS) in the assessment of the radiologic response of Crohn's disease strictures to treatment.Methods: The STRIDENT (Stricture Definition and Treatment) study was a randomized controlled trial of (2:1) intensive high-dose adalimumab combined with a thiopurine vs standard dose monotherapy adalimumab in patients with stricturing Crohn's disease. Clinical response was defined as a reduction in the Obstructive Symptom Score at 12 months. Intestinal ultrasound was performed at baseline, 4, 8, and 12 months and MRI at baseline and 12 months. This study examines secondary outcomes of stricture resolution and changes in stricture morphology with treatment.Results: Of 77 patients, 52 were in the intensive treatment group and 25 in the standard therapy group. Clinical response was achieved in 56 of 77 patients (73%). Complete stricture resolution occurred in 17 patients on IUS (29%) and 16 patients on MRI (22%). Stricture improvement occurred in 23 of 59 patients on IUS (39%) and 24 of 72 patients on MRI (33%). Bowel wall thickness improved at 12 months on both IUS (P < .0001) and MRI (P < .001) and was significantly lower in clinical responders (IUS P = .003) and those with fecal calprotectin < 100 µg/g (IUS P < .001; MRI P = .001).Conclusions: Radiologic severity of Crohn's disease strictures can improve with drug treatment, with complete stricture resolution observed in some. Intestinal ultrasound and MRI are effective modalities for monitoring the treatment response in patients with stricturing Crohn's disease (STRIDENT Drug Therapy Study: NCT03220841).","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143963523","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Monitoring Structural Bowel Damage in Patients With Crohn's Disease Using Intestinal Ultrasonography: Can It Be Reversed by Biological Treatment? 利用肠道超声监测克罗恩病患者的结构性肠损伤：生物治疗可以逆转吗？

IF 4.5 3区医学

Inflammatory Bowel Diseases Pub Date : 2025-05-08 DOI: 10.1093/ibd/izaf100

Sara Albert, Pilar Marqués, Ángela Algarra, Esther Blanc, María Jesús Pérez, José Richart, José María Paredes

{"title":"Monitoring Structural Bowel Damage in Patients With Crohn's Disease Using Intestinal Ultrasonography: Can It Be Reversed by Biological Treatment?","authors":"Sara Albert, Pilar Marqués, Ángela Algarra, Esther Blanc, María Jesús Pérez, José Richart, José María Paredes","doi":"10.1093/ibd/izaf100","DOIUrl":"10.1093/ibd/izaf100","url":null,"abstract":"Background: Currently, medical therapy of Crohn's disease (CD) can reduce the progression of some forms of structural bowel damage (SBD), but it does not prevent it. Once SBD has developed, it is important to assess the potential of medical treatments to reverse this damage.Aims: To determine whether transmural healing (TH), assessed by intestinal ultrasonography (IUS), can be achieved with medical treatment in CD patients with SBD compared to those without.Methods: A prospective, longitudinal, observational study was conducted to compare IUS monitoring at 3 and 12 months of treatment between CD patients with SBD prior to treatment and those with an inflammatory pattern.Results: Three months after starting treatment, patients without SBD had a significantly higher TH rate than those with SBD (25.8% vs 7.8%, respectively; P = .004). However, after 12 months, the TH rate was not significantly higher in patients without SBD compared to those with SBD (34% vs 26.6%, respectively; P = .317). During these 12 months, the need for corticosteroids, hospitalizations, and surgical resection was significantly higher in the SBD group.Conclusions: Biological treatment can reverse SBD in CD, but hospitalizations and surgery rates remain higher in this group.","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144022478","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Response to the Letter to the Editor: "AI-Assisted IBD Severity Classification: A Critical Perspective on Current Evidence and Next Steps". 对致编辑的信的回复：“人工智能辅助IBD严重程度分类：当前证据和下一步的关键观点”。

IF 4.5 3区医学

Inflammatory Bowel Diseases Pub Date : 2025-05-07 DOI: 10.1093/ibd/izaf096

Michelle Chae Min Lee, Armin Farahvash, Petros Zezos

引用次数: 0

Clinical Utility and Accuracy of Point-of-Care Testing for Anti-TNF Drug Monitoring and Loss of Response. 抗肿瘤坏死因子药物监测和反应丧失的即时检测的临床效用和准确性。

IF 4.5 3区医学

Inflammatory Bowel Diseases Pub Date : 2025-05-07 DOI: 10.1093/ibd/izaf101

Christoph Teichert, Suzanne I Anjie, Toer W Stevens, Bayda Bahur, Kurtis R Bray, Krisztina B Gecse, Geert R D'Haens

{"title":"Clinical Utility and Accuracy of Point-of-Care Testing for Anti-TNF Drug Monitoring and Loss of Response.","authors":"Christoph Teichert, Suzanne I Anjie, Toer W Stevens, Bayda Bahur, Kurtis R Bray, Krisztina B Gecse, Geert R D'Haens","doi":"10.1093/ibd/izaf101","DOIUrl":"https://doi.org/10.1093/ibd/izaf101","url":null,"abstract":"Background and aims: Point-of-care tests (POCT) enable immediate measurement of anti-TNF blood concentrations. This study examined the association between loss of response (LOR) to infliximab (IFX) or adalimumab (ADL) and serum concentrations measured with POCT and enzyme-linked immunosorbent assay (ELISA) in inflammatory bowel disease (IBD) patients.Methods: Patients with IBD with stored IFX or ADL serum samples were recruited. POCT was conducted, agreement with ELISA was evaluated using Bland-Altman plots. The primary endpoint was LOR defined as change in therapy, IBD-related surgery, new actively draining fistula, and/or endoscopic deterioration. ROC curves and quartile analysis assessed the association between concentrations and LOR.Results: A total of 176 patients were included (92 IFX/84 ADL, 154 Crohn's disease, and 22 ulcerative colitis). Median follow-up time was 20 months (interquartile range 9-38). LOR occurred in 37/84 (44%) ADL users and 55/92 (60%) IFX users. Median serum concentrations were significantly lower in LOR patients compared with sustained response, measured by both techniques for ADL (POCT: 6.45 vs 13.48 µg/mL, P <.001; ELISA: 4.80 vs 8.80 µg/mL, P <.001) and IFX (POCT: 2.39 vs 6.50 µg/mL, P <.001; ELISA: 1.70 vs 4.40 µg/mL, P <.001). Quartile analysis revealed that higher serum concentrations were associated with maintained response. ROC curve analysis demonstrated good or excellent discrimination for POCT and ELISA in association with LOR (AUC IFX: POCT = 0.82, ELISA = 0.76; AUC ADL: POCT = 0.82, ELISA = 0.81; all P <.0001). An overestimation of serum concentrations with POCT was observed.Conclusions: Serum ADL and IFX POCT concentrations are comparable to ELISA and associated with LOR, indicating its clinical utility.","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143984536","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Understanding Pouch-Related Fistulae: Don't Lose Track of Time. 了解与眼袋有关的瘘管：不要忘记时间。

IF 4.5 3区医学

Inflammatory Bowel Diseases Pub Date : 2025-05-07 DOI: 10.1093/ibd/izaf084

Sergio Bronze, Serre-Yu Wong, Haley Waite, Sergey Khaitov, Michael Plietz, Sue Hahn, Alexander Greenstein, Patricia Sylla, Jean-Frederic Colombel, Maia Kayal

引用次数: 0

Non-Typhoidal Salmonella Infections and Inflammatory Bowel Disease Risk: New Findings and Multidimensional Perspectives for Future Research. 非伤寒沙门氏菌感染和炎症性肠病风险：新发现和未来研究的多维视角。

IF 4.5 3区医学

Inflammatory Bowel Diseases Pub Date : 2025-05-05 DOI: 10.1093/ibd/izaf082

Yichen Feng, Shengfeng Wang, Sheng Li

引用次数: 0

The Way Forward in the Diagnosis and Treatment of IBDU in Children: A Global Perspective and Multidimensional Exploration. 儿童IBDU诊断和治疗的前进之路：全球视角和多维探索。

IF 4.5 3区医学

Inflammatory Bowel Diseases Pub Date : 2025-05-05 DOI: 10.1093/ibd/izaf104

Guilin Bai, Shengfeng Wang, Yuexia Zhang

引用次数: 0

Multifaceted Endoscopic Approach (Stricturotomy, Balloon Dilation, Fistulotomy, and Seton Placement) Guided by Intestinal Ultrasound to Avert Surgery in Complicated Crohn's Disease During Lactation. 多面内镜入路（狭窄切开术、球囊扩张术、瘘管切开术和塞顿置入术）在肠道超声引导下避免哺乳期复杂克罗恩病的手术。

IF 4.5 3区医学

Inflammatory Bowel Diseases Pub Date : 2025-05-02 DOI: 10.1093/ibd/izaf076

Partha Pal, Mohammad Abdul Mateen, Rajesh Gupta, Manu Tandan, D Nageshwar Reddy

引用次数: 0

Comparing Outcomes With Subcutaneous Infliximab (CT-P13 SC) by Baseline Immunosuppressant Use: A Post Hoc Analysis of the LIBERTY-CD and LIBERTY-UC Studies. 基线免疫抑制剂使用与皮下英夫利昔单抗（CT-P13 SC）的结果比较：LIBERTY-CD和LIBERTY-UC研究的事后分析

IF 4.5 3区医学

Inflammatory Bowel Diseases Pub Date : 2025-04-30 DOI: 10.1093/ibd/izaf038

Stefan Schreiber, Jean-Frederic Colombel, Stephen B Hanauer, William J Sandborn, Silvio Danese, Sang Joon Lee, Sung Hyun Kim, Yun Ju Bae, Sun Hee Lee, Seul Gi Lee, Joon Ho Lee, Jong Min Kim, Ga Hee Park, Jimin Lee, Ju Hyun Lee, Chae Young Kim, Bruce E Sands

{"title":"Comparing Outcomes With Subcutaneous Infliximab (CT-P13 SC) by Baseline Immunosuppressant Use: A Post Hoc Analysis of the LIBERTY-CD and LIBERTY-UC Studies.","authors":"Stefan Schreiber, Jean-Frederic Colombel, Stephen B Hanauer, William J Sandborn, Silvio Danese, Sang Joon Lee, Sung Hyun Kim, Yun Ju Bae, Sun Hee Lee, Seul Gi Lee, Joon Ho Lee, Jong Min Kim, Ga Hee Park, Jimin Lee, Ju Hyun Lee, Chae Young Kim, Bruce E Sands","doi":"10.1093/ibd/izaf038","DOIUrl":"https://doi.org/10.1093/ibd/izaf038","url":null,"abstract":"Background: Superior efficacy of subcutaneous infliximab (CT-P13 SC) over placebo for maintenance therapy in patients with Crohn's disease (CD) and ulcerative colitis (UC) was demonstrated in the randomized LIBERTY-CD and LIBERTY-UC studies. The current post hoc analysis compared outcomes with CT-P13 SC by baseline immunosuppressant use.Methods: Patients with moderately to severely active CD or UC randomized to the CT-P13 SC maintenance arm of the 54-week LIBERTY trials at week 10 and who were treated in the open-label extension (weeks 56-102) were included. Pharmacokinetic, efficacy, biomarker, safety, and immunogenicity endpoints were evaluated by baseline immunosuppressant use (monotherapy vs combination therapy).Results: A total of 192 patients with CD (monotherapy, n = 126; combination therapy, n = 66) and 237 patients with UC (monotherapy, n = 180; combination therapy, n = 57) were included. In both studies, efficacy outcomes were generally comparable between monotherapy and combination therapy at week 54 or week 102. Serum concentrations were generally higher, and antidrug antibody-positive conversion rates were lower, with combination therapy relative to monotherapy. In combined analyses of CD and UC, comparable safety profiles were observed between monotherapy and combination therapy.Conclusions: Despite some differences in pharmacokinetics and immunogenicity between CT-P13 SC received alone or in combination with immunosuppressants in patients with CD or UC, efficacy outcomes at week 54 or week 102 were generally comparable. The overall safety profile and incidence of systemic injection reactions were also comparable between monotherapy and combination therapy.","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144009280","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Diagnosing the Overlap: Metastatic Crohn's Disease With Hidradenitis Suppurativa-Like Features. 诊断重叠：转移性克罗恩病与化脓性汗腺炎样特征

IF 4.5 3区医学

Inflammatory Bowel Diseases Pub Date : 2025-04-29 DOI: 10.1093/ibd/izaf083

Elena Plakotaris, Ty Theriot, Collins Langley, Christopher Haas, Lacey Falgout

引用次数: 0